The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD
Open accessAbstract
PURPOSE: Severe (grade 3-4) acute graft-versus-host disease (AGVHD) is a major cause of death after unrelated-donor (URD) hematopoietic cell transplant (HCT), resulting in particularly high mortality after HLA-mismatched transplantation. There are no approved agents for AGVHD prevention, underscoring the critical unmet need for novel therapeutics. ABA2 was a phase II trial to rigorously assess safety, efficacy, and immunologic effects of adding T-cell costimulation blockade with abatacept to calcineurin inhibitor (CNI)/methotrexate (MTX)-based GVHD prophylaxis, to test whether abatacept could decrease AGVHD. METHODS: ABA2 enrolled adults and children with hematologic malignancies under two strata: a randomized, double-blind, placebo-controlled stratum (8/8-HLA-matched URD), comparing CNI/MTX plus abatacept with CNI/MTX plus placebo, and a single-arm stratum (7/8-HLA-mismatched URD) comparing CNI/MTX plus abatacept versus CNI/MTX CIBMTR controls. The primary end point was day +100 grade 3-4 AGVHD, with day +180 severe-AGVHD-free-survival (SGFS) a key secondary end point. Sample sizes were calculated using a higher type-1 error (0.2) as recommended for phase II trials, and were based on predicting that abatacept would reduce grade 3-4 AGVHD from 20% to 10% (8/8s) and 30% to 10% (7/8s). ABA2 enrolled 142 recipients (8/8s, median follow-up = 716 days) and 43 recipients (7/8s, median follow-up = 708 days). RESULTS: In 8/8s, grade 3-4 AGVHD was 6.8% (abatacept) versus 14.8% (placebo) ( P = .13, hazard ratio = 0.45). SGFS was 93.2% (CNI/MTX plus abatacept) versus 82% (CNI/MTX plus placebo, P = .05). In the smaller 7/8 cohort, grade 3-4 AGVHD was 2.3% (CNI/MTX plus abatacept, intention-to-treat population), which compared favorably with a nonrandomized matched cohort of CNI/MTX (30.2%, P < .001), and the SGFS was better (97.7% v 58.7%, P < .001). Immunologic analysis revealed control of T-cell activation in abatacept-treated patients. CONCLUSION: Adding abatacept to URD HCT was safe, reduced AGVHD, and improved SGFS. These results suggest that abatacept may substantially improve AGVHD-related transplant outcomes, with a particularly beneficial impact on HLA-mismatched HCT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
Lee, S. J., Klein, J., Haagenson, M., Baxter-Lowe, L. A., Confer, D. L., Eapen, M., Fernandez-Vina, M., Flomenberg, N., Horowitz, M., Hurley, C. K., et al. (2007) · Blood · doi:10.1182/blood-2007-06-097386 · Cited by 1,255
HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry
Gragert, L., Eapen, M., Williams, E., Freeman, J., Spellman, S., Baitty, R., Hartzman, R., Rizzo, J. D., Horowitz, M., Confer, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmsa1311707 · Cited by 1,103
Laughlin, M. J., Barker, J., Bambach, B., Koc, O. N., Rizzieri, D. A., Wagner, J. E., Gerson, S. L., Lazarus, H. M., Cairo, M., Stevens, C. E., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106143442402 · Cited by 882
Finke, J., Bethge, W. A., Schmoor, C., Ottinger, H. D., Stelljes, M., Zander, A. R., Volin, L., Ruutu, T., Heim, D. A., Schwerdtfeger, R., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70225-6 · Cited by 727
Risk factors for acute GVHD and survival after hematopoietic cell transplantation
Jagasia, M., Arora, M., Flowers, M. E. D., Chao, N. J., McCarthy, P. L., Cutler, C. S., Urbano-Ispizua, A., Pavletic, S. Z., Haagenson, M. D., Zhang, M.-J., et al. (2012) · Blood · doi:10.1182/blood-2011-06-364265 · Cited by 707
Ciurea, S. O., Zhang, M.-J., Bacigalupo, A. A., Bashey, A., Appelbaum, F. R., Aljitawi, O. S., Armand, P., Antin, J. H., Chen, J., Devine, S. M., et al. (2015) · Blood · doi:10.1182/blood-2015-04-639831 · Cited by 662
Transplantation of Anergic Histoincompatible Bone Marrow Allografts
Guinan, E. C., Boussiotis, V. A., Neuberg, D., Brennan, L. L., Hirano, N., Nadler, L. M., & Gribben, J. G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906033402202 · Cited by 429
Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials
Rubinstein, L. V., Korn, E. L., Freidlin, B., Hunsberger, S., Ivy, S. P., & Smith, M. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.149 · Cited by 408
Raiola, A. M., Dominietto, A., di Grazia, C., Lamparelli, T., Gualandi, F., Ibatici, A., Bregante, S., Van Lint, M. T., Varaldo, R., Ghiso, A., et al. (2014) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2014.05.029 · Cited by 283
Cited by
Acute graft-versus-host disease
Malard, F., Holler, E., Sandmaier, B. M., Huang, H., & Mohty, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00438-1 · Cited by 268
Metadata
- Authors
- Watkins, B., Qayed, M., McCracken, C., Bratrude, B., Betz, K., Suessmuth, Y., Yu, A., Sinclair, S., Furlan, S., Bosinger, S., Tkachev, V., Rhodes, J., Tumlin, A. G., Narayan, A., Cribbin, K., Gillespie, S., Gooley, T. A., Pasquini, M. C., Hebert, K., Kapoor, U., Rogatko, A., Tighiouart, M., Kim, S., Bresee, C., Choi, S. W., Davis, J., Duncan, C., Giller, R., Grimley, M., Harris, A. C., Jacobsohn, D., Lalefar, N., Norkin, M., Farhadfar, N., Pulsipher, M. A., Shenoy, S., Petrovic, A., Schultz, K. R., Yanik, G. A., Waller, E. K., Levine, J. E., Ferrara, J. L., Blazar, B. R., Langston, A., Horan, J. T., & Kean, L. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2021-06-10
- Volume
- 39
- Issue
- 17
- Pages
- 1865-1877
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3120895755
- Cited by
- 264
- References
- 25
- FWCI
- 23.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. https://app.cochat.ai/papers/10.1200/jco.20.01086
- The paper
- Watkins, B., Qayed, M., McCracken, C., Bratrude, B., Betz, K., Suessmuth, Y., Yu, A., Sinclair, S., Furlan, S., Bosinger, S., Tkachev, V., Rhodes, J., Tumlin, A. G., Narayan, A., Cribbin, K., Gillespie, S., Gooley, T. A., Pasquini, M. C., Hebert, K., . . . Kean, L. S. (2021). Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. Journal of Clinical Oncology. https://doi.org/10.1200/jco.20.01086
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.